Cost-utility analysis of primary prophylaxis versus secondary prophylaxis with granulocyte colony-stimulating factor in elderly patients with diffuse aggressive lymphoma receiving curative-intent chemotherapy

Journal of Clinical Oncology

Volumn 30, Issue 10, 2012, Pages 1064-1071

  Chan, Kelvin K W ^a,b,c,d   Siu, Eric ^d   Krahn, Murray D ^c,d   Imrie, Kevin ^d   Alibhai, Shabbir M H ^c,d  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; RITUXIMAB; VINCRISTINE;

AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIFFUSE AGGRESSIVE LYMPHOMA; DRUG COST; DRUG EFFICACY; FEBRILE NEUTROPENIA; HOSPITALIZATION COST; HUMAN; LYMPHOMA; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK REDUCTION; SECONDARY PREVENTION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MARKOV CHAINS; MIDDLE AGED; ONTARIO; PRIMARY PREVENTION; QUALITY-ADJUSTED LIFE YEARS; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 84863902271     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.36.8647     Document Type: Article

References (54)

1. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002 (Pubitemid 34438862)
2. [No authors listed]: A predictive model for aggressive non-Hodgkin's lymphoma: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994, 1993
3. [No authors listed]: Effect of age on the characteristics and clinical behavior of non-Hodgkin's lymphoma patients: The Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 8:973-978, 1997
4. [No authors listed]: A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma: The Non-Hodgkin's Lymphoma Classification Project. Blood 89:3909-3918, 1997
5. Morrison VA, Picozzi V, Scott S, et al: The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: A risk factor analysis. Clin Lymphoma 2:47-56, 2001 (Pubitemid 32677850)
6. Gómez H, Mas L, Casanova L, et al: Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocytemacrophage colony-stimulating factor: Identification of two age subgroups with differing hematologic toxicity. J Clin Oncol 16:2352-2358, 1998 (Pubitemid 28309027)
7. Avilés A, Nambo MJ, Talavera A, et al: Epirubicin (CEOP-Bleo) versus idaurubicin (CIOP-Bleo) in the treatment of elderly patients with aggressive non-Hodgkin's lymphoma: Dose escalation studies. Anticancer Drugs 8:937-942, 1997 (Pubitemid 28027091)
8. Bertini M, Freilone R, Vitolo U, et al: The treatment of elderly patients with aggressive non-Hodgkin's lymphomas: Feasibility and efficacy of an intensive multidrug regimen. Leuk Lymphoma 22: 483-493, 1996 (Pubitemid 26341015)
9. Gisselbrecht C, Haioun C, Lepage E, et al: Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: Factors influencing chemotherapy administration-Groupe d'Etude des Lymphomes de l'Adulte. Leuk Lymphoma 25:289-300, 1997 (Pubitemid 27248180)
10. Osby E, Hagberg H, Kvaløy S, et al: CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: Results of a Nordic Lymphoma Group randomized trial. Blood 101:3840-3848, 2003 (Pubitemid 36857855)
11. Sonneveld P, de Ridder M, van der Lelie H, et al: Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 13:2530-2539, 1995
12. Tirelli U, Errante D, Van Glabbeke M, et al: CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: Results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol 16:27-34, 1998 (Pubitemid 28041575)
13. Zinzani PL, Storti S, Zaccaria A, et al: Elderly aggressive-histology non-Hodgkin's lymphoma: First-line VNCOP-B regimen experience on 350 patients. Blood 94:33-38, 1999 (Pubitemid 29300131)
14. Bohlius J, Herbst C, Reiser M, et al: Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev 4: CD003189, 2008
15. Kuderer NM, Dale DC, Crawford J, et al: Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: A systematic review. J Clin Oncol 25:3158-3167, 2007 (Pubitemid 47218066)
16. Lyman GH, Crawford J, Culakova E, et al: Overall survival of lymphoma patients in randomized controlled trials comparing primary G-CSF chemotherapy support to control. Presented at the 52nd American Society of Hematology Annual Meeting and Exposition, Orlando, FL, December 4-7, 2010
17. Lyman GH, Dale DC, Wolff DA, et al: Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: A systematic review. J Clin Oncol 28:2914-2924, 2010
18. Smith TJ, Khatcheressian J, Lyman GH, et al: 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 24:3187-3205, 2006 (Pubitemid 46638957)
19. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology. http://www.nccn.org/index.asp
20. Kouroukis CT, Haynes AE: The prophylactic use of filgrastim in patients with hematological malignancies. CED-CCO Special Advice Report #14-1. Cancer Care Ontario. Report Date: September 23, 2009. http://www.cancercare.on.ca/ toolbox/qualityguidelines/other-reports/evaldrug-rep/
21. Aapro MS, Bohlius J, Cameron DA, et al: 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8-32, 2011
22. Zagonel V, Babare R, Merola MC, et al: Costbenefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy. Ann Oncol 5:127-132, 1994 (suppl 2)
23. Lyman GH, Kuderer N, Greene J, et al: The economics of febrile neutropenia: Implications for the use of colony-stimulating factors. Eur J Cancer 34:1857-1864, 1998 (Pubitemid 28535432)
24. Timmer-Bonte JN, Adang EM, Smit HJ, et al: Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibodies in small-cell lung cancer. J Clin Oncol 24: 2991-2997, 2006 (Pubitemid 46638931)
25. Kuderer NM, Dale DC, Crawford J, et al: Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106: 2258-2266, 2006 (Pubitemid 43673249)
26. Glaspy JA, Bleecker G, Crawford J, et al: The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy. Eur J Cancer 29A:S23-S30, 1993 (suppl 7)
27. Ramsey SD, Liu Z, Boer R, et al: Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy. Value Health 12:217-225, 2009
28. Elting LS, Lu C, Escalante CP, et al: Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol 26:606-611, 2008 (Pubitemid 351264355)
29. Weycker D, Malin J, Edelsberg J, et al: Cost of neutropenic complications of chemotherapy. Ann Oncol 19:454-460, 2008 (Pubitemid 351325664)
30. Leese B: The costs of treating febrile neutropenia in six U.K. hospitals. Eur J Cancer 29A:S15-S18, 1993 (suppl 7)
31. Crawford J, Dale DC, Kuderer NM, et al: Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: The results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw 6:109-118, 2008 (Pubitemid 351340522)
32. Chrischilles E, Delgado DJ, Stolshek BS, et al: Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin's lymphoma. Cancer Control 9:203-211, 2002 (Pubitemid 34657282)
33. Doorduijn JK, van der Holt B, van Imhoff GW, et al: CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol 21:3041-3050, 2003 (Pubitemid 46606283)
34. Barosi G, Marchetti M, Liberato NL: Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia. Br J Cancer 78:781-787, 1998 (Pubitemid 28418314)
35. Uyl-de Groot CA, Hagenbeek A, Verdonck LF, et al: Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediateand high-grade malignant non-Hodgkin's lymphoma (NHL). Bone Marrow Transplant 16:463-470, 1995
36. Brown RE, Hutton J, Burrell A: Cost effectiveness of treatment options in advanced breast cancer in the UK. Pharmacoeconomics 19:1091-1102, 2001 (Pubitemid 33135697)
37. Launois R, Reboul-Marty J, Henry B: A costutility analysis of second line chemotherapy in metastatic breast cancer: Docetaxel versus paclitaxel versus vinorelbine. Pharmacoeconomics 10:504-521, 1996 (Pubitemid 26359879)
38. Chang RW, Pellisier JM, Hazen GB: A cost-effectiveness analysis of total hip arthroplasty for osteoarthritis of the hip. JAMA 275:858-865,1996 (Pubitemid 26087223)
39. Ontario Case Costing Initiative. http://www. occp.com/mainPage.htm
40. Community Care Access Centre. http://www .ccac-ont.ca/Content.aspx? EnterpriseID=15& LanguageID=1&MenuID=55
41. Ontario Ministry of Health and Long-Term Care: Schedule of Benefits for Physician Services under the Health Insurance Act. http://www.health .gov.on.ca/english/providers/program/ohip/sob/physserv/physserv-mn.html
42. Tufts Medical Center: Cost-Effectiveness Analysis (CEA) Registry. https://research.tufts-nemc.org/cear/default.aspx
43. Briggs A, Claxton K, Sculpher M: Decision Modelling for Health Economic Evaluation. Oxford, United Kingdom, Oxford University Press, 2006
44. Briggs AH: Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 17:479-500, 2000
45. Sung L, Nathan PC, Alibhai SM, et al: Meta-analysis: Effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med 147:400-411, 2007 (Pubitemid 351664541)
46. Lyman GH, Morrison VA, Dale DC, et al: Risk of febrile neutropenia among patients with intermediategrade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymphoma 44:2069-2076, 2003 (Pubitemid 37369646)
47. Scott SD, Chrischilles EA, Link BK, et al: Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin's lymphoma treated with chemotherapy. J Manag Care Pharm 9:15-21, 2003
48. Weycker D, Hackett J, Edelsberg JS, et al: Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother 40:402-407, 2006
49. Laupacis A, Feeny D, Detsky AS, et al: How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 146:473-481, 1992
50. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al: First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: A multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23:1178-1184, 2005 (Pubitemid 46202274)
51. Pettengell R, Bosly A, Szucs TD, et al: Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: Data from the INC-EU Prospective Observational European Neutropenia Study. Br J Haematol 144:677-685, 2008
52. Lathia N, Mittmann N, DeAngelis C, et al: Evaluation of direct medical costs of hospitalization for febrile neutropenia. Cancer 116:742-748, 2010
53. Cosler LE, Sivasubramaniam V, Agboola O, et al: Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy. Value Health 8:47-52, 2005 (Pubitemid 40293640)
54. Pfreundschuh M, Schubert J, Ziepert M, et al: Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: A randomised controlled trial (RICOVER-60). Lancet Oncol 9:105-116, 2008